Prosecution Insights
Prosecution Insights
Technology area: Medical Devices & Mechanical Engineering
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Vibrato Medical Inc. currently manages 2 pending office actions within the Medical Devices & Mechanical Engineering technology area. These actions are distributed across 2 distinct examiners. However, both matters are being processed within 1 distinct art unit, which suggests a unified administrative environment for the company's current filings. This concentration may provide some consistency in the technical standards applied to the filings.
NGANGA, BONIFACE N is identified as the busiest examiner for the portfolio. This examiner is responsible for 1 busiest examiner pending action. Given that there are 2 pending office actions in total, this examiner handles a portion of the current workload. The remaining portion is managed by the other of the distinct examiners, creating a distribution of the pending office actions across the individuals involved. This balanced approach avoids over-reliance on a single person for the entire portfolio.
The use of a sole art unit for the Medical Devices & Mechanical Engineering area is a significant factor for practitioners to consider. While they must still address the individual examination styles of the distinct examiners, the shared administrative framework is beneficial. The 2 pending office actions represent the entirety of the company's immediate prosecution efforts. Success in these matters will depend on navigating the specific requirements of the sector and the individual preferences of the assigned examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGANGA, BONIFACE N | 1 | 64.2% | +28.8% |
| TURCHEN, ROCHELLE DEANNA | 1 | 57.5% | +29.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18829102 | EXTRACORPOREAL THERAPEUTIC ULTRASOUND FOR PROMOTING ANGIOGENESIS | NGANGA, BONIFACE N | 47d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18829102 | EXTRACORPOREAL THERAPEUTIC ULTRASOUND FOR PROMOTING ANGIOGENESIS | NGANGA, BONIFACE N | 47d |
| 18819840 | EXTRACORPOREAL THERAPEUTIC ULTRASOUND FOR PROMOTING ANGIOGENESIS | TURCHEN, ROCHELLE DEANNA | — |
| Art Unit | Apps |
|---|---|
| 3797 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18829102 | EXTRACORPOREAL THERAPEUTIC ULTRASOUND FOR PROMOTING ANGIOGENESIS | NGANGA, BONIFACE N | 3797 | §103§112 | Non-Final OA | 47d | Pending | Sep 09, 2024 |
| 18819840 | EXTRACORPOREAL THERAPEUTIC ULTRASOUND FOR PROMOTING ANGIOGENESIS | TURCHEN, ROCHELLE DEANNA | 3797 | §103Other | Non-Final OA | — | Pending | Aug 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial